Company intelligence / Profile preview
Alys Pharmaceuticals
Boston, Massachusetts, United Statesalyspharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Alys Pharmaceuticals launched in 2024 with a $100M investment from Medicxi by merging six asset-centric companies. The company has over a dozen programs targeting immune-inflammatory and autoimmune skin diseases. Its lead program ALY‑101, an intradermal injectable JAK1 siRNA-lipid conjugate for alopecia areata, entered Phase IIa trials in early 2025 after FDA/Health Canada clearance. Multiple clinical proof-of-concept readouts across the pipeline are expected by 2027. The company leverages multiple advanced modalities and collaborates with leading academic institutions to address both prevalent and underserved dermatological indications[1][3][7].
- Therapeutic areas
- HematologyImmunologyOncologyDermatology
- Modalities
- siRNA (small interfering RNA)PeptidesAntibodiesVectorized small moleculesCovalent conjugates[2][5][10]
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
Request access →03
Partnerships
No major pharma partnerships announced as of May 2025; strong academic collaborations noted.
Beyond the preview
Go deeper on Alys Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alys Pharmaceuticals.